Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
749.92
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
October 02, 2024
RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing growth opportunities in the U.S. Type 1 and Type 2 diabetes markets, product...
Via
Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
October 02, 2024
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.
Via
Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
October 02, 2024
Eli Lilly announces a $4.5B investment to build the Lilly Medicine Foundry, a state-of-the-art facility in Indiana. The new center will focus on advanced drug development and manufacturing, reinforcing...
Via
Benzinga
Eli Lilly's Options: A Look at What the Big Money is Thinking
October 01, 2024
Via
Benzinga
Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points
September 30, 2024
Via
Benzinga
Is NYSE:LLY a Fit for high Growth Investing Strategies?
September 26, 2024
Exploring ELI LILLY & CO (NYSE:LLY)'s high growth characteristics.
Via
Chartmill
3 Momentum Trades Too Good Pass Up
October 02, 2024
Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going.
Via
MarketBeat
Topics
ETFs
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
October 02, 2024
Eli Lilly is on track to become the first trillion-dollar pharma company, fueled by FDA-approved weight loss drugs. With a current valuation of $842 billion, analysts weigh investor risks as...
Via
Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
Via
Investor Brand Network
Eli Lilly Unusual Options Activity
September 25, 2024
Via
Benzinga
Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients
October 01, 2024
Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent health risks. CEO Dave Ricks emphasizes responsible use amid supply concerns.
Via
Benzinga
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
October 01, 2024
Currently, the BMI cut-off for trials is 27 in the U.S. and northern Europe.
Via
Benzinga
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
September 30, 2024
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC...
Via
Benzinga
Exposures
Product Safety
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
September 30, 2024
Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting...
Via
Benzinga
This Is the Best Pharma Stock to Invest $1,000 in Right Now
September 29, 2024
Eli Lilly could keep growing for years without changing its strategy.
Via
The Motley Fool
Eli Lilly And Co DCF Valuation: Is The Stock Undervalued?
September 29, 2024
Based on the DCF valuation, the stock is overvalued. The DCF value of $632.57 share is lower than the current market price of $921.49. The Margin of Safety is -45.67%.
Via
Talk Markets
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
September 28, 2024
These two players are set on finding the next big therapeutic modality.
Via
The Motley Fool
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
September 28, 2024
It's hard to bet against this company right now.
Via
The Motley Fool
Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever
September 28, 2024
Eli Lilly and Lululemon operate in very different industries, but both are on promising trajectories.
Via
The Motley Fool
Stocks To Buy And Hold For 5 Years
September 27, 2024
Growth potential is key for investors who want to buy and hold for 5 years.
Via
Talk Markets
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
September 27, 2024
Eli Lilly is focusing on research and manufacturing.
Via
The Motley Fool
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
September 26, 2024
The company is working on a drug that mimics apelin, which is released following exercise.
Via
Investor's Business Daily
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
September 26, 2024
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Via
The Motley Fool
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
September 25, 2024
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
Via
Benzinga
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
September 25, 2024
A new study suggests semaglutide drugs like Ozempic, used for type 2 diabetes, may lower the risk of opioid overdose in patients with opioid use disorder. Findings highlight the need for more research...
Via
Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
September 25, 2024
Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.
Via
Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
September 25, 2024
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.